Ozone, Efferocytosis, and Neuropathic Pain

Study Background and Research Question

Neuropathic pain is driven by nerve injury or disease-associated dysfunction and commonly includes spontaneous pain, sensory abnormalities, hyperalgesia, and mechanical hypersensitivity. Although several drug classes are used clinically, efficacy is often incomplete and treatment can be limited by adverse effects, tolerance, or dependence. This therapeutic gap has increased interest in the cellular events that sustain neuroinflammation after peripheral nerve injury.

The reference study focuses on one such event: the accumulation of apoptotic cells. Injured tissues can contain dying cells that release danger-associated signals when they are not removed efficiently. Macrophage efferocytosis—the recognition, engulfment, and processing of apoptotic cells—normally helps resolve inflammation, but impaired clearance may allow inflammatory signaling to persist. Ruan and colleagues therefore asked whether ozone could improve apoptotic-cell removal and, in turn, reduce neuropathic pain. Their findings are reported in Frontiers in Immunology.

Key Innovation from the Reference Study

The central innovation is the proposed connection between ozone exposure, macrophage efferocytosis, and pain relief through a defined signaling axis. Rather than treating macrophages only as sources of inflammatory mediators, the study examines their capacity to clear apoptotic neutrophils and presents this clearance function as a potentially actionable component of neuropathic-pain biology.

According to the reference study, ozone activated AMP-activated protein kinase, or AMPK, increased Gas6 expression, and stimulated MerTK, a receptor involved in apoptotic-cell recognition. The authors further associated this response with increased SOCS3 and reduced expression of the inflammatory factors IL-1β, IL-6, and TNF-α. The pathway was not presented as a simple increase in every efferocytosis-related ligand: Gas6 was upregulated, whereas Protein S was not reported to change in the same way. This distinction gives the proposed mechanism greater specificity than a general claim that ozone broadly activates macrophages.

Importantly, pharmacological interruption strengthened the causal interpretation. The analgesic effect of ozone was abolished by an AMPK inhibitor and by the MerTK inhibitor UNC2541, as described in the published study. These experiments do not establish that every step is exclusively dependent on the pathway, but they support AMPK and MerTK as functional nodes rather than merely correlated markers.

Methods and Experimental Design Insights

The investigators used a chronic constriction injury model in mice to reproduce key features of peripheral neuropathic pain. Animals received different ozone concentrations, allowing the researchers to compare treatment responses rather than relying on a single exposure level. Mechanical hypersensitivity was used as the principal behavioral outcome, while tissue and cellular analyses addressed apoptotic-cell accumulation, inflammatory signaling, and macrophage activity.

The experimental design also included an in vitro macrophage assay. Bone-marrow-derived macrophages were exposed to apoptotic neutrophils after ozone treatment, and their phagocytic activity was examined. This two-level strategy was valuable because the animal model connected ozone exposure with pain behavior, whereas the cell system offered a more direct test of whether macrophages themselves displayed enhanced efferocytosis.

Mechanistic experiments then combined pathway measurements with inhibitor studies. AMPK activation, Gas6 and Protein S expression, MerTK signaling, SOCS3 expression, and inflammatory cytokines were assessed in the context of ozone treatment. The use of both an AMPK inhibitor and a MerTK receptor inhibitor helped position the pathway in an ordered model: AMPK activation was associated with Gas6/MerTK signaling, which was linked to improved apoptotic-cell clearance and a less inflammatory macrophage state.

Protocol Parameters

• Animal model: chronic constriction injury mice were used to study ozone-associated changes in mechanical hypersensitivity and inflammatory pathology, as reported in the reference study.
• Ozone comparison: the investigators tested 15 mg, 30 mg, and 45 mg ozone conditions; the 30 mg condition produced the most notable reduction in mechanical hypersensitivity in the reported experiments.
• Cellular efferocytosis assay: bone-marrow-derived macrophages were challenged with apoptotic neutrophils to evaluate whether ozone altered phagocytic clearance in vitro.
• Mechanistic interruption: AMPK inhibition with CC and MerTK inhibition with UNC2541 were used to test whether the proposed pathway was required for the antinociceptive response.
• Workflow recommendation: dose-response, behavioral, efferocytosis, and cytokine measurements should be analyzed as related but distinct endpoints; increased phagocytosis alone should not be interpreted as proof of pathway activation.

Core Findings and Why They Matter

The first major finding was that ozone reduced mechanical hypersensitivity in chronic constriction injury mice, with the 30 mg condition identified as the effective concentration in the reported comparison. This result places ozone within an experimental framework for modulating neuropathic pain rather than viewing it only as a nonspecific oxidant exposure.

The second finding was a measurable increase in macrophage phagocytic activity toward apoptotic neutrophils. In the context of nerve injury, this observation is important because it suggests that the inflammatory environment may be influenced not only by cytokine production but also by the efficiency with which dying cells are removed.

The third finding was mechanistic. Ozone activated AMPK, increased Gas6, stimulated MerTK, and enhanced SOCS3 expression. These molecular changes were accompanied by lower IL-1β, IL-6, and TNF-α levels. Because the AMPK and MerTK inhibitors blocked the beneficial pain-related effects, the authors argue that the AMPK/Gas6-MerTK/SOCS3 axis is functionally involved in ozone-mediated analgesia. The study therefore connects a cellular housekeeping process—efferocytosis—with the resolution of inflammatory signals relevant to pain.

For researchers, the broader implication is experimental as much as therapeutic. Efferocytosis can be treated as a quantitative phenotype that may help distinguish inflammation-resolving macrophage responses from simple changes in macrophage abundance or cytokine secretion. This distinction could improve interpretation of future studies examining immune regulation in neuropathic pain.

Comparison with Existing Internal Articles

The internal article Ozone Enhances Macrophage Efferocytosis to Relieve Neuropathic Pain presents an accessible summary of the same AMPK/Gas6-MerTK/SOCS3 interpretation. Its value is primarily explanatory: it foregrounds the relationship between apoptotic-cell clearance and reduced neuroinflammation. The reference paper remains the source for the dose comparison, inhibitor experiments, and experimental distinction between Gas6 and Protein S.

A complementary resource, BCECF for Extracellular pH in Efferocytosis, approaches the problem from an assay-design perspective. It discusses how extracellular proton dynamics can be measured alongside macrophage and efferocytosis experiments. This is relevant to the ozone study as an adjunct measurement strategy, but it should not be mistaken for evidence that extracellular pH mediated the reported AMPK/Gas6-MerTK/SOCS3 effects.

Why this cross-domain matters, maturity, and limitations

Linking pH measurement with efferocytosis and neuropathic-pain research may help researchers characterize the extracellular microenvironment surrounding immune cells. A fluorescent pH probe for ion transport studies, for example, could be used in a parallel assay to determine whether ozone-associated changes in macrophage behavior coincide with altered proton dynamics. Similarly, a probe for cellular metabolism pH monitoring could support studies of how macrophage metabolic state changes during apoptotic-cell uptake.

However, this cross-domain application is a complementary research direction, not a result established by the reference paper. The reported experiments identify AMPK, Gas6, MerTK, SOCS3, and inflammatory cytokines as central readouts; they do not demonstrate that pH changes caused the observed effects. Any microenvironmental pH regulation assay should therefore be calibrated independently and interpreted alongside, rather than substituted for, efferocytosis and signaling measurements.

Limitations and Transferability

Several limitations affect how broadly the findings can be applied. First, the in vivo evidence comes from a mouse chronic constriction injury model. Such models reproduce selected features of neuropathic pain but do not capture the full clinical heterogeneity of pain caused by diabetes, chemotherapy, autoimmune disease, or diverse nerve injuries. Translation to patients will require confirmation in additional models and careful evaluation of ozone exposure, delivery, and safety.

Second, the study combines pharmacological inhibitors with molecular and behavioral outcomes. Inhibitors are useful for testing pathway involvement, but off-target activity, dose selection, and tissue exposure can influence interpretation. Genetic approaches or receptor-selective validation could further test the proposed ordering of AMPK, Gas6, MerTK, and SOCS3.

Third, enhanced efferocytosis does not automatically mean complete inflammatory resolution. The quality of apoptotic-cell processing, the persistence of macrophage activation, and the balance of local mediators may all matter. The study provides evidence for reduced inflammatory cytokines and improved pain behavior, but it does not establish whether these changes persist long term or whether repeated ozone exposure produces the same response.

Finally, extracellular pH was not a demonstrated mediator in the reference experiments. Researchers who add pH measurements should treat them as contextual data. An acid-base homeostasis research tool may reveal changes associated with treatment or cell metabolism, but such observations would require separate perturbation experiments before being assigned a causal role.

Research Support Resources

For studies that extend the reported workflow with extracellular or compartmental pH measurements, researchers can use BCECF (2',7'-bis(carboxyethyl)-5(6)-Carboxyfluorescein), SKU C5694. This membrane-impermeant, dual-excitation ratiometric pH indicator is described for quantitative measurements in the physiological range; the product information reports a pKa of approximately 6.98 and a readout based on emission near 535 nm after excitation at 490 and 440 nm. It can therefore support a microenvironmental pH regulation assay or extracellular pH measurement alongside, but not in place of, the reference study's efferocytosis, pathway, cytokine, and behavioral endpoints.